Davina Gale

Following study at the University of Sussex, Davina has almost 20 years’ experience in the pharmaceutical industry working for GlaxoSmithKline and SmithKline Beecham, primarily in the identification and validation of novel PD biomarkers for neurological and respiratory disease, including transitioning their use into Phase I/IIa clinical trials. In 2009, she joined the Molecular and Computational Diagnostics group at the Cancer Research UK Cambridge Institute as the first member of Nitzan Rosenfeld’s lab, establishing protocols and lab infrastructure for the identification of rare mutations in circulating tumour DNA in the plasma of cancer patients.